Cancer immunotherapy based on DC-tumor fusion vaccine

Biotherapy

Volumn 21, Issue 1, 2007, Pages 48-55

  Iinuma, Hisae ^a   Okinaga, Kota ^a  

^a TEIKYO UNIVERSITY   (Japan)

Author keywords

Allogeneic dendritic cell; Allogeneic tumor cell; Clinical study; Dendritic cell; Fusion vaccine

Indexed keywords

ANTINEOPLASTIC AGENT; DENDRITIC CELL VACCINE; TUMOR ANTIGEN;

ARTICLE; CANCER; CANCER IMMUNOTHERAPY; CANCER STAGING; CELL FUSION; CLINICAL TRIAL; DENDRITIC CELL; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; TUMOR CELL;

EID: 33847041004     PISSN: 09142223     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Gong, J., Chen, D., Kashiwaba, M., et al.: Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat. Med. 3: 558-561, 1997.
2. Chang, A.E., Redman, B.G. and Whitfield, J.R.: A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin. Cancer Res. 8: 1021-1032, 2002.
3. Matsuda, K., Tsunoda, T., Tanaka, H., et al.: Enhancement of cytotoxic T-lymphocyte responses in patients with gastrointestinal malignancies following vaccination with CEA peptide-pulsed dendritic cells. Cancer Immunol. Immunother. 53: 609-616, 2004.
4. Nair, S.K., Morse, M., Boczkowski, D., et al.: Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. Ann. Surg. 235: 540-549, 2002.
5. Ogawa, F., Iinuma, H. and Okinaga, K.: Dendritic cell vaccine therapy by immunization with fusion cells of interleukin-2 gene-transduced, spleen derived dendritic cells and tumor cells. Scand. J. Immunol. 59: 432-439, 2004.
6. Iinuma, H., Okinaga, K., Fukushima, R., et al.: Superior protective and therapeutic effects of IL-12 and IL-18 gene-transduced dendritic neuroblastoma fusion cells on liver metastasis of murine neuroblastoma. J. Immunol. 176: 3461-3469, 2006.
7. Kjaergaard, J., Shimizu, K. and Zuyu, S.: Electrofusion of syngeneic dendritic cells and tumor generates potent therapeutic vaccine. Cell. Immunol. 225: 65-74, 2003.
8. Hiraoka, K., Yamamoto, S., Otsuru, S., et al.: Enhanced tumor-specific long-term immunity of hemaggluttinating virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodexynucleotides. J. Immunol 173: 4297-4307, 2004.
9. Shimizu, K., Kuriyama, H., Kjaergaard, J., et al.: Comparative analysis of antigen loading strategies of dendritic cells for tumor immunotherapy. J. Immunother. 27: 265-272, 2004.
10. Kikuchi, T., Akasaki, Y., Irie, M., et al.: Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol. Immunother. 50: 337-344, 2001.
11. Kikuchi, T., Akasaki, Y., Abe, T., et al.: Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J. Immunother. 27: 452-459, 2004.
12. Trefzer, U., Herberth, G., Wohlan, K., et al.: Vaccination with hybrids of tumor and dendritic cells induces tumor-specific T-cell and clinical responses in melanoma stage III and IV patients. Int. J. Cancer 110: 730-740, 2004.
13. Krause, S.W., Neumann, C., Soruri, A., et al.: The treatment of patients with disseminated malignant melanoma by vaccination with autologous cell hybrids of tumor cells and dendritic cells. J. Immunother. 25: 421-428, 2002.
14. Avigan, D., Vasir, B., Gong, J., et al.: Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin. Cancer Res. 10: 4699-4708, 2004.
15. Homma, S., Kikuchi, T., Ishiji, N., et al.: Cancer immunotherapy by fusions of dendritic and tumor cells and rh-IL-12. Eur. J. Clin. Invest. 35: 279-286, 2005.
16. Haenssle, H.A., Krause, S.W., Emmer, S., et al.: Hybrid cell vaccination in metastatic melanoma: clinical and immunologic results of a phase I/II study. J. Immunother. 27: 147-155, 2004.
17. Marten, A., Renoth, S., Heinicke, T., et al.: Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma. Hum. Gene Ther. 14: 483-494, 2003.
18. Fabre, J.W.: The allogeneic response and tumor immunity. Nat. Med. 7: 649-652, 2001.
19. Suzuki, T., Fukuhara, T., Tanaka, M., et al.: Vaccination of dendritic cells loaded with interleukin-12-secreting cancer cells augments in vivo antitumor immunity: characteristics of syngeneic and allogeneic antigen-presenting cell cancer hybrid cells. Clin. Cancer Res. 11: 58-66, 2005.
20. Lundqvist, A., Palmborg, A., Bidla, G., et al.: Allogeneic tumor-dendritic cell fusion vaccine for generation of broad prostate cancer T-cell responses. Med. Oncol. 21: 155-165, 2004.